Join us for a virtual event with Humacyte.  Top line results from Humacyte’s Phase 2/3 V005 trial evaluating the Human Acellular Vessel (HAV) in vascular trauma will be reported.  The HAV is an off-the-shelf, universally implantable bioengineered human tissue, that is being studied in traumatic injury and other vascular diseases.  The top line results will serve as the basis for BLA filing for the HAV with the FDA later in 2023.  The event will also feature Dr. Michael Curi who will discuss the unmet clinical need in vascular trauma, and the use of the HAV as a potential extremity repair solution.

The HAV has received priority designation for the treatment of vascular trauma by the U.S. Department of Defense and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.

A live question and answer session will follow the formal presentations.